Vaxcyte, Inc. $PCVX Shares Bought by Advisors Asset Management Inc.

Advisors Asset Management Inc. raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 81.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,929 shares of the company’s stock after purchasing an additional 867 shares during the period. Advisors Asset Management Inc.’s holdings in Vaxcyte were worth $73,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. AlphaQuest LLC acquired a new stake in Vaxcyte in the first quarter valued at approximately $33,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Vaxcyte in the first quarter worth approximately $35,000. Parallel Advisors LLC boosted its stake in shares of Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock worth $61,000 after acquiring an additional 1,071 shares during the last quarter. IFP Advisors Inc boosted its stake in shares of Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock worth $62,000 after acquiring an additional 1,306 shares during the last quarter. Finally, Twin Tree Management LP boosted its stake in shares of Vaxcyte by 301.3% in the first quarter. Twin Tree Management LP now owns 2,365 shares of the company’s stock worth $89,000 after acquiring an additional 3,540 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Stock Performance

Shares of Vaxcyte stock opened at $32.17 on Friday. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The company has a market cap of $4.18 billion, a price-to-earnings ratio of -7.83 and a beta of 1.04. The business’s 50 day moving average price is $33.16 and its 200 day moving average price is $39.28.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.10). During the same period in the previous year, the firm posted ($1.10) earnings per share. On average, analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PCVX has been the topic of a number of research analyst reports. The Goldman Sachs Group initiated coverage on Vaxcyte in a research note on Friday. They issued a “neutral” rating and a $38.00 price target on the stock. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $106.25.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.